Fr1da Study
The Fr1da study, the world's largest population-based screening for type 1 diabetes in children, was launched at Helmholtz Munich in 2015.
The Fr1da offers islet autoantibody screening to children aged 2 to 10 years, living in Bavaria, Germany, with the aim to diagnose type 1 diabetes at a presymptomatic stage to
- prevent life-threatening diabetic ketoacidosis (DKA)
- minimize psychological burden and uncertainty by education and care of those affected
- help to set new standards for early diagnosis of type 1 diabetes
- identify children who benefit from immune-based therapies to prevent insulin dependence
Children with a family history of type 1 diabetes (first- or second-degree relative) can participate in screening between the ages of 1 and 21 years. All children can participate twice within the respective age ranges.
The Fr1da study, the world's largest population-based screening for type 1 diabetes in children, was launched at Helmholtz Munich.
The Fr1da offers islet autoantibody screening to children aged 2 to 10 years, living in Bavaria, Germany, with the aim to diagnose type 1 diabetes at a presymptomatic stage to
- prevent life-threatening diabetic ketoacidosis (DKA)
- minimize psychological burden and uncertainty by education and care of those affected
- help to set new standards for early diagnosis of type 1 diabetes
- identify children who benefit from immune-based therapies to prevent insulin dependence
Children with a family history of type 1 diabetes (first- or second-degree relative) can participate in screening between the ages of 1 and 21 years. All children can participate twice within the respective age ranges.
